Residual kidney function (RKF) contributes significant solute clearance in hemodialysis patients. Kidney Diseases Outcomes Quality Initiative (KDOQI) guidelines suggest that hemodialysis dose can be safely reduced in those with residual urea clearance (KRU) of 2 ml/min/1.73 m 2 or more. However, serial measurement of RKF is cumbersome and requires regular interdialytic urine collections. Simpler methods for assessing RKF are needed. b-trace protein (bTP) and b2-microglobulin (b2M) have been proposed as alternative markers of RKF. We derived predictive equations to estimate glomerular filtration rate (GFR) and KRU based on serum bTP and b2M from 191 hemodialysis patients based on standard measurements of KRU and GFR (mean of urea and creatinine clearances) using interdialytic urine collections. These modeled equations were tested in a separate validation cohort of 40 patients. A prediction equation for GFR that includes both bTP and b2M provided a better estimate than either alone and contained the terms 1/bTP, 1/b2M, 1/serum creatinine, and a factor for gender. The equation for KRU contained the terms 1/bTP, 1/b2M, and a factor for ethnicity. Mean bias between predicted and measured GFR was 0.63 ml/min and 0.50 ml/min for KRU. There was substantial agreement between predicted and measured KRU at a cut-off level of 2 ml/min/1.73 m 2 . Thus, equations involving bTP and b2M provide reasonable estimates of RKF and could potentially be used to identify those with KRU of 2 ml/min/1.73 m 2 or more to follow the KDOQI incremental hemodialysis algorithm.
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R esidual kidney function (RKF) is of significant prognostic importance to patients on hemodialysis (HD). 1 It has many clinical advantages including improved nutrition, 2 anemia, and phosphate control. 3 Even small amounts of RKF can provide significant benefit.
The Kidney Diseases Outcomes Quality Initiative (KDOQI) suggests that minimum dialysis Kt/V targets may be reduced in those with residual urea clearance (KRU) $2 ml/min/1.73 m 2 . The European Best Practice Guidelines (EBPG) recommend measuring RKF in HD patients using the mean of urea and creatinine clearances and offer suggestions to incorporate this into the HD prescription to allow individual adjustment of dialysis prescription to meet minimum dialysis adequacy targets. 4, 5 However, measurement of urea and creatinine clearances requires an interdialytic urine collection, 6 which can be difficult and inconvenient for patients because RKF has to be monitored at least every 1 to 3 months for incremental HD to be practiced safely. 7 Serum biomarkers that obviate the need for regular urine collections would be desirable.
Urea and creatinine are imperfect biomarkers of kidney function because of external influences by factors such as muscle mass, gender, diet, and nutritional status. Hence there has been interest in novel alternative serum biomarkers, especially cystatin C, b-trace protein (bTP), and b2-microglobulin (b2M). [8] [9] [10] [11] Use of cystatin C in dialysis patients is limited because nonrenal clearance of cystatin C is significant and greatly exceeds its renal clearance in this setting. 12, 13 bTP is a 23 kDa glycoprotein, also known as lipocalin type prostaglandin D synthase, and is expressed in a number of organs including the brain, retina, testes, heart, and kidney.
14 It is virtually exclusively excreted by the kidneys, 15 and serum levels of bTP concentration correlate well with residual urine volumes in HD patients, 16 though its ability to predict RKF in the HD setting has not been explored. b2-microglobulin (b2M) has a molecular weight of 11.8 kDa and accumulates in kidney failure. b2M levels have a close relationship with RKF in HD 17 and peritoneal dialysis. 18, 19 RKF is the most significant determinant of b2M levels in HD patients and has a greater influence on these levels than the convective clearance provided by hemodiafiltration (HDF). 17, 20 Hence bTP and b2M are promising candidates as predictors of RKF in the HD setting. have been implicated.
The aim of this study was to evaluate the usefulness of bTP and b2M as estimates of RKF in HD patients. Clinical determinants of bTP and b2M in the HD setting were explored, and prediction equations to estimate residual urea clearance (KRU) and glomerular filtration rate (GFR) in HD patients were constructed based on serum levels of bTP and b2M. The predictive equations were compared with KRU and GFR measured using interdialytic urea and creatinine clearances in a separate validation cohort of HD patients. We also explored the ability of predictive equations to identify HD patients with KRU $2 ml/ min/1.73 m 2 to follow the KDOQI incremental HD algorithm.
RESULTS

Characteristics of the study cohort
The study cohort consisted of 231 prevalent HD patients based at the East & North Herts NHS Trust; 191 patients were randomly selected into a modeling group for derivation of equations for predicting parameters of RKF based on serum levels of bTP and b2M, and the remaining 40 patients were used for validation of the final constructed equations (Table 1 ). There were no significant differences between the modeling and validation cohorts in terms of age, anthropometric parameters, ethnicity, blood pressure, dialysis adequacy, diabetes prevalence, primary renal disease, and
Charlson co-morbidity index. Serum bTP and b2M concentrations were similar in both groups. The modeling cohort had a higher GFR than the validation cohort (1.72 vs. 0.74 ml/ min/1.73 m 2 ), whereas the validation cohort had a higher prevalence of malignant disease and a higher median C-reactive protein level.
Clinical determinants of bTP and b2M
Clinical determinants of serum bTP and b2M levels in HD were sought using univariable and multivariable regression analysis of clinical and demographic data from the modeling cohort. Independent predictors of bTP and b2M are shown in Table 2 and Table 3 , respectively.
Predictors of bTP
In multivariable analysis, significant positive associations with bTP were found for male gender and the prevalence of atheromatous disease (Table 2 ). There were inverse associations for age, body surface area, GFR, and treatment with HDF. Caucasian ethnicity, prevalence of malignant disease, ultrafiltration volume, dialyzer Kt/V, diuretic use, and mean interdialytic weight gain were associated with bTP in univariable analysis only.
Predictors of b2M
In multivariable analysis, significant associations with b2M
were found with GFR and diabetic status (Table 3) . Weight, male gender, dialysis vintage, ultrafiltration volume, mean interdialytic weight gain, dialyzer Kt/V, and diuretic use were associated in univariable analysis only. No significant associations were found with C-reactive protein, HDF treatment, or convective volume.
Development of prediction equations for KRU and GFR using bTP and b2M Linear regression models for KRU and GFR were determined using the modeling cohort in three phases: (i) using bTP alone, (ii) using b2M alone, and (iii) using both bTP and b2M.
Other relevant covariates were used in each case. The best constructed models are shown in Table 4 . Integrated Discrimination Improvement analysis 25 was used to assess the predictive accuracy of the equation that incorporated both bTP and b2M (model 3) compared with the best model using a single biomarker (model 1 or 2) for cut-off levels 1 to 5 ml/min for both KRU and GFR. This demonstrated that predictive equations that use both bTP and b2M had greater accuracy than the best equation using a single protein (b2M) at cut-off levels of measured clearance ranging from 1 to 5 ml/min. This was true for both estimated GFR and KRU. For instance, at a cut-off KRU >2 ml/min/1.73 m 2 , the integrated discrimination improvement index was 0.216 for the combined equation compared with 0.171 for the equation using b2M alone (P ¼ 0.001). Likewise, at a cut-off GFR >2 ml/min/ Where for ethnicity, Caucasian ¼ 1, Non-Caucasian ¼ 0 Leave-out one-cross validation for estimated GFR and KRU demonstrated a pseudo-R 2 of 0.66 and 0.60, respectively, which were similar to the performance of the above regression equations in the modeling cohort (R 2 ¼ 0.70 and 0.63, respectively).
Evaluation of predictive equations
The best modeled predictive equations for estimating KRU and GFR were compared with measured KRU and GFR (using urinary urea and creatinine clearances) in the modeling and validation cohorts using correlation and Bland-Altman analysis. 26 Level of agreement for different cut-off levels of residual kidney function was assessed using the kappa statistic (k). Estimated and measured values of both parameters correlated significantly in both modeling (correlation coefficients for KRU and GFR were 0.781 and 0.801, respectively [P < 0.001]) and validation cohorts (correlation coefficient for KRU and GFR were 0.783 and 0.762, respectively [P < 0.001]). Mean bias between measured and estimated KRU in the validation cohort was -0.50 ml/min [95% CI -0.25 to -0.75] with 95% limits of agreement from -2.03 to 1.04 ml/min. For GFR, mean bias was -0.64 ml/min [95% CI -0.89 to -0.39] with 95% limits of agreement from -2.84 to 1.57 ml/min ( Figure 1 ).
Level of agreement using the kappa statistic (k) 27 between the proportions of patients with measured and predicted levels of GFR above cut-offs in the range 1 to 3 ml/min/1.73 m 2 was substantial in the modeling cohort (k ¼ 0.65-0.67, all P < 0.001) and ranged from moderate to substantial in the validation cohort (k ¼ 0.43-0.77, all P < 0.01). Similarly, level of agreement for KRU above cut-offs in the range 1 to 3 ml/min/1.73 m 2 was moderate to substantial in the modeling cohort (k ¼ 0.51-0.66, all P < 0.001) and fair to substantial in the validation cohort (k ¼ 0.36-0.65, all P < 0.02). For both GFR and KRU, the level of agreements deteriorated outside of these ranges. 
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Application of predictive equations for KRU and GFR to KDOQI incremental hemodialysis algorithm
The diagnostic accuracy of predictive equations to identify those with KRU >2 ml/min/1.73 m 2 , which might allow safe reduction of minimum dialysis Kt/V targets as suggested in the KDOQI Hemodialysis Adequacy guidelines, was assessed in modeling and validation groups. Receiving operator characteristic analyses were performed for prediction of various cutoff levels of measured GFR or KRU using the prediction equations in both the modeling and validation cohorts. The prediction equations demonstrated a high degree of accuracy with area under curve values between 0.900 and 0.948 (Table 5 ). For instance, identifying patients in the modeling cohort with measured levels of KRU >2 ml/min/1.73 m 2 , using cut-off predicted KRU levels >2 ml/min/1.73 m 2 yielded an area under curve of 0.903, a sensitivity of 58%, and a specificity 92%, while in the validation cohort corresponding values were area under curve 0.948, sensitivity 71%, and specificity 94%.
Using our modeled equation for estimating KRU, we determined the proportion of patients whose minimum target Kt/V could be safely reduced according to KDOQI Hemodialysis Adequacy guidelines. 4 In the modeling cohort, estimated levels of KRU >2 ml/min/1.73 m 2 correctly identified patients with measured values above and below this cut-off level in 81.2% subjects. In 13.6% of the cohort, KRU was falsely estimated to be less than 2 ml/min/1.73 m 2 (false negative) and falsely estimated to be greater than 2 ml/min/1.73 m In the validation cohort, patients with KRU >2 ml/min/ 1.73 m 2 were correctly identified in 90% of cases. False-positive rate was 5%. Of these, mean underestimation between measured KRU and the critical cut-off level of 2 ml/min/ Although b2M clearance is superior in HDF, HD modality was not an independent determinant of serum b2M levels. 17, 20 The high prevalence of significant RKF in this cohort, a more important determinant of b2M levels than even convective clearance, may be a factor. 20 Predictive equations for GFR and KRU correlated well with measured GFR and KRU. The integrated discrimination improvement index demonstrated superior diagnostic ability when both bTP and b2M were incorporated into regression models. The best constructed regression equation using both biomarkers could explain 63% and 70% of KRU and GFR variance, respectively; however, a substantial amount of variation still remains unexplained. Mean bias between measured and estimated parameters of RKF was -0.5 ml/min for KRU and -0.64 ml/min for GFR, with wide limits of agreement. Our findings suggest that equations incorporating serum levels of bTP and b2M may not be accurate enough to estimate GFR if RKF were to be used to calculate minimum HD targets as advocated by Gotch 30 and Casino and Lopez. 5, 28, 31 KDOQI guidelines propose an alternative, relatively simple approach for including RKF into HD prescription. This confines attempts to reduce dialysis dose to patients with a KRU of 2 ml/min/1.73 m 2 or more, assuming RKF to be absent below this. 4 We have examined whether equations incorporating bTP and b2M could be used to accurately distinguish patients with KRU >2 ml/min/1.73 m 2 , thus allowing safe implementation of the KDOQI algorithm.
Applying our modeled equations to estimate KRU at cut-off >2 ml/min/1.73 m 2 in the validation cohort demonstrated substantial agreement with measured KRU (k ¼ 0.654). Our modeled equations incorrectly estimated KRU to be $2 ml/ min/1.73 m 2 in 5.0% to 5.2% of patients, suggesting that only a small proportion of patients would receive underdialysis if KRU estimates were used to set minimum dialysis Kt/V targets according to the KDOQI algorithm.
There were a number of limitations to our study. The number of patients in validation cohorts was relatively small (n ¼ 40). Modeled equations based on a small sample size may limit applicability to the general population because other co-morbid factors, such as inflammation, active lupus, and malignancy, may affect levels of bTP 9 and b2M. 21, 22 Similarly, the modeled regression equations were based on a relatively homogenous population with a high proportion treated with HDF. Our findings may not apply to other 
patient cohorts of different ethnic mix, body composition, and HDF prevalence. We have used the arithmetic mean of pre-and post-levels of urea and creatinine because this is a commonly used method for calculating GFR and KRU. It does, however, risk potential inaccuracies related to the non-linear interdialytic increments of both urine excretion and the plasma solute levels.
bTP and b2M measurements were carried out using nephelometric and turbidimetric techniques, respectively. Alternative methods are available for both proteins, 32, 33 and variation between different assays may therefore limit applicability of our equations. Additionally, although the precision of both assays seems robust in non-uremic serum, we cannot exclude the potential interference of the assay by toxins related to advanced uremia or the dialysis procedure; however, the manufacturer does not preclude reporting of these analytes in uremic samples. Both bTP and b2M are removed during high-flux HD and HDF, and the concentrations of both increase during the interdialytic period. b2M levels exceed 95% of predialysis levels 44 hours after session end. 13 It is likely, therefore, that the predialysis levels after the long interdialytic gap will equal or exceed the previous predialysis value. We know of no comparable data for bTP, but, by the same logic, the level after the long gap is likely to be the most indicative of peak levels. Hence levels of these biomarkers immediately before the first dialysis of the week are likely to be the most suitable for predicting RKF. Levels at other times may overestimate RKF. The levels of both these parameters will also vary according to the volume status of these patients but to a lesser extent.
Serial b2M levels increase with declining RKF, 34 and though there are no comparable data for bTP, a similar relationship would be expected. However, our modeled prediction equations were developed using b2M, bTP, and RKF measurements at a single time point. Hence the equations may not perform similarly in predicting progressive loss of RKF from serial levels as would be the case if there were differences in the relative rates of change of B2M and bTP levels with progressive loss of RKF. Further work is required to examine this issue before clinical application of our findings. Finally, measurement of GFR using interdialytic urine collections may be prone to error, and ideally the regression equations should be validated against a gold-standard method of GFR measurement such as 125 I-iothalamate or chromium-51 labeled ethylenediamine tetraacetic acid. However, these techniques are impractical for routine clinical use, and the primary objective of this investigation was to determine whether equations involving bTP and/or b2M could replace standard measurements of GFR and KRU using interdialytic urine collections.
In summary, serum levels of bTP and b2M are reasonable indicators of RKF. Inclusion of both into regression equations can provide a better estimate of RKF than either molecule alone. However, serum levels of bTP and b2M may not be accurate enough to replace the standard estimation of GFR using urea and creatinine clearances for HD units practicing an incremental HD regime, although the predictive equations using bTP and b2M could potentially be used to identify those with KRU > 2 ml/min/1.73 m 2 to follow the suggested KDOQI incremental HD algorithm. Validation of this approach in larger, more diverse cohorts of patients is required.
MATERIALS AND METHOD Ethical approval
The study was approved by the East Midlands National Research Ethics Committee. Informed consent was obtained from all studied patients.
Overall study design This is a single-center cross-sectional study of prevalent patients undergoing outpatient HD at the East & North Hertfordshire NHS Trust. The center deploys an incremental approach to dialysis prescription involving monthly urine collections while patients continue to pass urine. Around 80% are treated by HDF, the remainder using high-flux HD. All were clinically stable at the time of the study. Patients with positive HIV status and active hepatitis infection were excluded. Two hundred thirty-one patients (n ¼ 231) were recruited. Recruitment was carried out prospectively to ensure that around two thirds of the total cohort had RKF. Patients who produced less than 200 ml of urine volume over the interdialytic period were considered to have no RKF-clearances were not measured in these patients. Of the total cohort, 191 were randomly assigned to the modeling group for derivation of the predictive equations and the remaining 40 were assigned to the validation group.
bTP, b2M, KRU, and GFR, calculated from the mean urea and creatinine clearance, were measured in all patients. Demographic, clinical, and dialysis data including age, gender, Charlson co-morbidity index, dialysis modality, Kt/V, and C-reactive protein were also collected.
Measurement of residual kidney function: mean urea and creatinine clearance Blood was sampled at the end of the first dialysis session of the week and immediately before the next session. Between these samples, urine was collected over the whole interdialytic period. GFR was estimated as mean of the urea and creatinine clearances. These clearances were calculated using the formula:
¼ plasma concentration at the end of the first dialysis session, and C preHD2 ¼ plasma concentrations is the plasma concentration immediately before the start of the second dialysis session. Post-dialysis urea and creatinine measurements were adjusted for rebound using the Smye formula 35 in accordance with the European Best Practice Hemodialysis guidelines. 5 Measurement of serum b-trace protein and b2-microglobulin Blood samples for serum bTP and b2M were taken pre-dialysis immediately before the first HD session of the week. Serum bTP was measured with particle-enhanced immune-nephelometric assay (N Latex bTP assay; Siemens Diagnostics, Newark, DE, USA), and serum b2M was measured using by immune-turbidimetric analysis (Olympus AU640; Beckman-Coulter, Brea, CA). Manufacturersupplied data showed that coefficient of variation for bTP and b2M assays were <6.1% and <10%, respectively. 36, 37 As judged by external quality assessment, coefficient of variation for the b2M assay during the period of study was 3.9% at a mean concentration of 3 mg/L and 4.5% at a mean concentration of 6.6 mg/L. For bTP, coefficient of variation was 3.8% at a mean concentration of 0.826 mg/ L and 2.6% at a mean concentration of 12.4 mg/L.
Statistical analysis
Data are reported as medians with interquartile ranges (IQR). Comparisons between groups were made using the Mann-Whitney U test. For categorical data, the chi-square test was used to assess group differences.
Determining independent predictors of bTP and b2M
Linear regression analysis was used to identify significant determinants of bTP and b2M. Potentially significant demographic, clinical, and dialysis parameters were entered into the regression model to determine the most significant predictors alone, and both biomarkers together along with relevant covariates were constructed using linear regression modeling. Independent variables were examined for multi-collinearity. All independent variables had a variance inflation factor <3, suggesting minimal collinearity in the regression models. Residual plots were inspected for normality and homoscedasticity. The Integrated Discrimination Improvement index 25 was used to assess the predictive accuracy of the equation that incorporated both biomarkers over the best model using a single protein for cut-off levels 1 to 5 ml/min for both KRU and GFR. To assess for potential overfitting of regression models for estimated GFR and KRU, leave-out one cross validation was applied to the entire cohort (modeling plus validation) to calculate pseudo-R 2 for the predictive equations.
Evaluation of predictive equations for KRU and GFR Correlation was between measured and estimated (from equations) for KRU and GFR using Spearman's correlation coefficient. BlandAltman 26 analysis was used to compare measured and estimated KRU and GFR in the validation cohort. Level of agreement between measured and predicted KRU and GFR at different cut-off levels was assessed using the kappa statistic. 27 Receiving operator characteristic analysis was performed for prediction of various cut-off levels of measured GFR and KRU using prediction equations in both modeling and validation cohorts.
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